Had a quick look in this morning and although I agree Aspire affect the share price I also believe the valuation is set by how much we know about each trial etc.,
Leo in purchasing PolyMedix has added a whole new portfolio of drug candidates giving great underlying value to the company. I look for a sharp break out soon based on speculation before Brilacidin results are announced and a major move up if they are good.
Looking at the bigger picture (our 2 year chart), it's pretty clear to me our k trial (elephant in the room) has been, and currently is, the driving force behind our SP. The market is waiting on data or trial results. Until then, we remain range bound w/ or w/o Aspire. It's as simple as that.